Skip to main content

Osteoporosis

140
Pipeline Programs
30
Companies
50
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
35
2
27
2
50
24
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2782%
Monoclonal Antibody
412%
Small Molecule
26%
+ 225 programs with unclassified modality

On Market (2)

Approved therapies currently available

Eli Lilly and Company
FORTEOApproved
teriparatide
Eli Lilly and Company
Parathyroid Hormone Analog [EPC]subcutaneous2002
425M Part D
Amgen
EVENITYApproved
romosozumab-aqqg
Amgen
injection2019
1M Part D

Competitive Landscape

60 companies ranked by most advanced pipeline stage

Prevail Therapeutics
5
8
10
TeriparatidePhase 4Peptide
TeriparatidePhase 4Peptide
TeriparatidePhase 4Peptide
TeriparatidePhase 4Peptide
TeriparatidePhase 4Peptide
+25 more programs
Sandoz
SandozAustria - Kundl
25 programs
2
15
4
Hormone replacement therapyPhase 4
RaloxifenePhase 4
zoledronic acidPhase 4
zoledronic acidPhase 4
LetrozolePhase 3Small Molecule
+20 more programs
ViiV Healthcare
ViiV HealthcareNC - Durham
16 programs
9
1
1
2
IbandronatePhase 4
ibandronatePhase 4
alendronate with cholecalciferolPhase 3
RonacaleretPhase 2
RonacaleretPhase 1
+11 more programs
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
8 programs
1
Control groupN/A
DocumentationN/A
Falls, Fractures & Osteoporosis Risk Assessment & ManagementN/A1 trial
ForteoN/A1 trial
patient magazineN/A1 trial
+3 more programs
Active Trials
NCT00465387Completed400Est. Jan 2006
NCT01155245Unknown60Est. Jan 2025
NCT01109472Completed1,009Est. Nov 2012
+3 more trials
Amgen
AmgenTHOUSAND OAKS, CA
5 programs
1
2
ProliaPhase 41 trial
TetracyclinePhase 4Small Molecule1 trial
EVENITY(romosozumab)Phase 3Monoclonal Antibody5 trials
Control groupN/A
DocumentationN/A
Active Trials
NCT06973109Not Yet Recruiting36Est. Jun 2027
NCT07366086Recruiting71Est. May 2028
NCT05972551Recruiting106Est. Aug 2027
+4 more trials
Hanlim Pharm
2 programs
2
Risedronate/Cholecalciferol combinationPhase 41 trial
Risedronate/Cholecalciferol combinationPhase 41 trial
Active Trials
NCT01675297Completed1,053Est. Apr 2014
NCT01904110Completed196Est. Mar 2016
Leo Pharma
1 program
1
Hormone replacement therapyPhase 4
Kite Pharma
1 program
1
tenofovir-alafenamide-emtricitabinePhase 4
MSD
MSDIreland - Ballydine
28 programs
7
6
8
AlendronatePhase 31 trial
MK0217, alendronate sodium / Duration of Treatment: 1 MonthPhase 31 trial
MK0217A, alendronate sodiumPhase 31 trial
OdanacatibPhase 31 trial
OdanacatibPhase 31 trial
+23 more programs
Active Trials
NCT00512499Completed1,410Est. Jul 2016
NCT00139425Completed10,000Est. Dec 2004
NCT00145080Completed4,685Est. Jan 2006
+25 more trials
Sharp Therapeutics
7
6
8
AlendronatePhase 3
MK0217, alendronate sodium / Duration of Treatment: 1 MonthPhase 3
MK0217A, alendronate sodiumPhase 3
OdanacatibPhase 3
OdanacatibPhase 3
+23 more programs
Human BioSciences
3
3
1
Increased calcium intakePhase 31 trial
AlendronatePhase 21 trial
Soluble Corn FiberPhase 21 trial
TMTDSPhase 21 trial
Incorporating More Physical Activity and Calcium in TeensPhase 11 trial
+3 more programs
Active Trials
NCT01394484Completed12Est. Feb 2013
NCT00067925Completed718Est. Jun 2002
NCT00222872Completed61Est. Sep 2008
+5 more trials
Alliance Pharmaceuticals
3 programs
1
RisedronatePhase 31 trial
Effects of Exemestane on Bone StrengthN/A1 trial
Falls, Fractures & Osteoporosis Risk Assessment & ManagementN/A
Active Trials
NCT01144468Completed351Est. Jan 2022
NCT01611571Completed31Est. Nov 2011
Abbott
AbbottABBOTT PARK, IL
2 programs
1
1
AlendronatePhase 31 trial
FructooligosaccharidePhase 1/2
Active Trials
NCT00236002Terminated182Est. Aug 2009
Innovation Pharmaceuticals
1
FOSAMAXPhase 31 trial
Active Trials
NCT00822029Terminated2Est. Feb 2011
Xentria
1 program
1
MAB-22Phase 31 trial
Active Trials
NCT06504966Withdrawn0Est. Oct 2027
Pharmbio Korea
1
PBK_L2201Phase 31 trial
Active Trials
NCT06154187Unknown60Est. Nov 2025
Nordic Pharma
1 program
1
SMC021 Oral calcitoninPhase 3
AryoGen Pharmed
1
denosumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03293108Unknown190Est. Sep 2020
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
denosumab biosimilarPhase 3
Astellas
AstellasChina - Shenyang
2 programs
1
1
YM529 / ONO-5920Phase 2/3
ONO-5920 / YM529Phase 11 trial
Active Trials
NCT00965978Completed48Est. Sep 2009
Ono Pharmaceutical
1
1
YM529 / ONO-5920Phase 2/31 trial
ONO-5334Phase 21 trial
Active Trials
NCT00532337Completed285
NCT00794443Completed692Est. Apr 2010
Biocorp
2 programs
1
EBP05Phase 2
SBD111 medical foodN/A
Angitia Biopharmaceuticals
Angitia BiopharmaceuticalsCA - Woodland Hills
1 program
1
AGA2118Phase 23 trials
Active Trials
NCT07361354Recruiting30Est. Nov 2026
NCT06577935Active Not Recruiting379Est. Mar 2028
NCT05225857Completed90Est. Jan 2024
Entera Bio
1 program
1
EBP05Phase 21 trial
Active Trials
NCT04003467Completed161Est. May 2021
Purdue Pharma
Purdue PharmaCT - Stamford
5 programs
2
1
FructooligosaccharidePhase 1/21 trial
GalactooligosaccharidePhase 11 trial
Genistein vs RisedronatePhase 11 trial
0 grams SCFN/A1 trial
No soluble corn fiberN/A1 trial
Active Trials
NCT01660503Completed30Est. Apr 2014
NCT01571440Completed24Est. Jul 2010
NCT01263847Completed31Est. Jul 2010
+2 more trials
UNION therapeutics
1
minodronic acidPhase 11 trial
No additional intervention will be administered.N/A1 trial
Active Trials
NCT05339425Completed50,000Est. Dec 2024
NCT02295436Completed48Est. Oct 2014
Hyundai Pharmaceutical Co
2
Bazedoxifene 20 mgPhase 11 trial
HDDO-1614Phase 11 trial
Active Trials
NCT03234244Completed37Est. Aug 2017
NCT03382314Completed38Est. Jan 2018
Yuyu Pharma
1 program
1
Maxmarvil®Phase 11 trial
Active Trials
NCT01526278Completed18Est. Sep 2012
Medica Corp
Medica CorpMA - Bedford
1 program
1
NaQuinatePhase 1
Medpace
MedpaceCINCINNATI, OH
1 program
1
abaloparatide-sMTSPhase 1

+30 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AmgenProlia
Amgenromosozumab
Radius HealthAbaloparatide
Gilead Sciencestenofovir-alafenamide-emtricitabine
AmgenTetracycline
Hanlim PharmRisedronate/Cholecalciferol combination
Eli Lilly and Companyteriparatide
Hanlim PharmRisedronate/Cholecalciferol combination
Eli Lilly and CompanyTeriparatide
GSKIbandronate
SanofiActonel
EisaiMenatetrenone
EisaiMENATETRANONE
Novo NordiskHormone replacement therapy
Amgenromosozumab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 25,450 patients across 50 trials

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

Start: Aug 2024Est. completion: Jan 2027102 patients
Phase 4Active Not Recruiting
NCT06079476Amgenromosozumab

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Start: Oct 2023Est. completion: Oct 2025100 patients
Phase 4Completed

Abaloparatide Before Total Knee Arthroplasty

Start: Jan 2020Est. completion: Apr 202558 patients
Phase 4Completed
NCT02815566Gilead Sciencestenofovir-alafenamide-emtricitabine

Bone Health in Aging HIV Infected Women

Start: Sep 2017Est. completion: Feb 202134 patients
Phase 4Completed
NCT02576652AmgenTetracycline

Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement

Start: Dec 2015Est. completion: Dec 20176 patients
Phase 4Completed
NCT01904110Hanlim PharmRisedronate/Cholecalciferol combination

To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women

Start: Dec 2012Est. completion: Mar 2016196 patients
Phase 4Completed

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

Start: Dec 2012Est. completion: Sep 201613 patients
Phase 4Completed
NCT01675297Hanlim PharmRisedronate/Cholecalciferol combination

Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis

Start: Jul 2011Est. completion: Apr 20141,053 patients
Phase 4Completed

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Start: Apr 2009Est. completion: Aug 2015224 patients
Phase 4Completed
NCT00327990GSKIbandronate

Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate

Start: Apr 2005Est. completion: Dec 2006300 patients
Phase 4Completed

Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy

Start: Jul 2002Est. completion: Dec 2004248 patients
Phase 4Completed
NCT00548509EisaiMenatetrenone

The Effect of Vitamin K2 on Bone Turnover

Start: Feb 2002Est. completion: Jan 2013131 patients
Phase 4Completed
NCT00165607EisaiMENATETRANONE

Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)

Start: Apr 1996
Phase 4Completed
NCT00252408Novo NordiskHormone replacement therapy

Danish Osteoporosis Prevention Study

Start: Oct 1990Est. completion: Dec 20032,000 patients
Phase 4Completed
NCT07366086Amgenromosozumab

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

Start: Mar 2026Est. completion: May 202871 patients
Phase 3Recruiting

Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

Start: Oct 2025Est. completion: Oct 20270
Phase 3Withdrawn
NCT05972551Amgenromosozumab

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Start: Apr 2024Est. completion: Aug 2027106 patients
Phase 3Recruiting

Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

Start: Feb 2024Est. completion: Nov 202560 patients
Phase 3Unknown

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Start: Oct 2021Est. completion: Nov 2023327 patients
Phase 3Completed
NCT04779216Amgenromosozumab

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

Start: Sep 2021Est. completion: Nov 202530 patients
Phase 3Completed

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Start: May 2018Est. completion: Sep 2021228 patients
Phase 3Completed
NCT03432533Amgenromosozumab

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Start: Feb 2018Est. completion: Jan 2020283 patients
Phase 3Completed

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women

Start: Apr 2017Est. completion: Sep 2020190 patients
Phase 3Unknown
NCT02791516Amgenromosozumab

A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Start: Jan 2017Est. completion: Dec 201867 patients
Phase 3Completed
NCT02186171Amgenromosozumab

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

Start: Jun 2014Est. completion: Apr 2016245 patients
Phase 3Completed
NCT02016716Amgenromosozumab

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Start: Dec 2013Est. completion: Dec 2014294 patients
Phase 3Completed
NCT01803607MSDodanacatib

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Start: Mar 2013Est. completion: Nov 2014135 patients
Phase 3Terminated
NCT01796301Amgenromosozumab

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Start: Jan 2013Est. completion: May 2015436 patients
Phase 3Completed
NCT01631214Amgenromosozumab

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Start: May 2012Est. completion: Jun 20174,093 patients
Phase 3Completed
NCT01552122MSDOdanacatib

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Start: May 2012Est. completion: Feb 20150
Phase 3Withdrawn
NCT01575834Amgenromosozumab

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

Start: Mar 2012Est. completion: Dec 20167,180 patients
Phase 3Completed
NCT01120600MSDOdanacatib

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Start: Jun 2010Est. completion: Jul 2013294 patients
Phase 3Completed

Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy

Start: Feb 2009Est. completion: Feb 20112 patients
Phase 3Terminated
NCT00729183MSDOdanacatib

Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Start: Oct 2008Est. completion: Mar 2011214 patients
Phase 3Completed

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis

Start: May 2008Est. completion: Jul 20121,262 patients
Phase 3Completed

Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

Start: Jul 2007Est. completion: Oct 201092 patients
Phase 3Completed
NCT00421343MSDalendronate with cholecalciferol

Secondary Prevention of Osteoporosis

Start: Feb 2007Est. completion: Jun 200829 patients
Phase 3Completed
NCT00365456TakedaParathyroid Hormone

Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

Start: Jul 2006Est. completion: Aug 2011407 patients
Phase 3Completed
NCT00400530MSDMK0217, alendronate sodium / Duration of Treatment: 1 Month

Upper GI Handling of Branded vs. Generic Alendronate

Start: Dec 200525 patients
Phase 3Completed

Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )

Start: Jul 2005Est. completion: Aug 2009182 patients
Phase 3Terminated

Open Label Extension

Start: Jan 2005Est. completion: Oct 200691 patients
Phase 3Completed

A New Active Vitamin D, ED-71 for Osteoporosis

Start: Sep 2004Est. completion: Oct 20081,056 patients
Phase 3Completed

Calcium Supplementation in Postmenopausal Women

Start: Jan 2004Est. completion: Mar 2005374 patients
Phase 3Completed
NCT00092079MSDMK0217A, alendronate sodium

A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)

Start: Jan 2004Est. completion: Nov 2004652 patients
Phase 3Completed

Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis

Start: Dec 2003Est. completion: Nov 201131 patients
Phase 3Completed

Open Label Extension Study of PREOS

Start: Oct 2001Est. completion: Apr 20051,683 patients
Phase 3Completed
NCT00062595Eisaiphylloquinone

Vitamin K and Bone Turnover in Postmenopausal Women

Start: Sep 2000Est. completion: Oct 2004375 patients
Phase 3Completed

IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)

Start: Aug 1999
Phase 3Completed
NCT00063024Human BioSciencesIncreased calcium intake

Program to Prevent Osteoporosis in Girls

Start: Jun 1999Est. completion: May 2004322 patients
Phase 3Unknown
NCT00000412MSDAlendronate

Osteoporosis Prevention After Heart Transplant

Start: Sep 1997Est. completion: Apr 2002149 patients
Phase 3Completed

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

50 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 25,450 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.